Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Catalent IncCTLT-40.682.643.2142.57-11.19%-2.86%46.91$60.69-$521.842,899,700$63.485

Detail of Catalent Inc

 
CEO
Mr. Alessandro Maselli
Employees
17000
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$12B

Company details

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Revenue
Cost of goods
Gross profit
OE
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$4.38B
Cost of goods (CoG)
-$3.42B
Gross profit (GP)
$965.00M
Operating expense (OE)
-$1.02B
General and administrative (G&A)
-$945.00M
Other (OTH)
-$80.00M
Operating income (OI)
-$60.00M
Other income expense (OIE)
-$722.00M
Pretax income (PI)
-$1.04B
Tax (TAX)
$37.00M
Net income (NI)
-$999.00M
Catalent Inc
CTLT • XNYS • US
$63.485
+14.06 (28.45%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.56
Margin profit
-9.34%
52 week low
$48.720001
52 week high
$63.494999
50-day simple moving average
$62.74
200-day simple moving average
$60.69
Percent held by insiders
0.50%
Percent held by institutions
87.87%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CTLT +28.45%
eps change
CTLT 0.00%